The CD4+:CD8+ T cell ratio is often used as a simple measure to determine the overall balance of T cell function in cancer, providing prognostic information when measured in the tumor and tumor-immune interface (Shah et al., 2011; Wang et al., 2017a). This evidence concerns the gene CD4 and cancer.